Movetis
Movetis was acquired by Shire in 2010 for €428 million. Movetis focused on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. It was created by a team of entrepreneurs led by Dirk Reyn as a spin-off from Johnson & Johnson. Its products address GI disorders, such as severe chronic constipation, ascites, pediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-esophageal reflux disease. Movetis brought to market Resolor, a drug for chronic constipation.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Exit
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.